Drug Trial Radar · NCT03778554
Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction
Last checked: Nov 19, 2026Latest source record: Jun 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,760
Planned (sponsor's estimate)
Start
Dec 17, 2018
Primary completion
Apr 1, 2025
Study completion Dec 10, 2035
Sponsor
- Lead sponsor
- Bispebjerg HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Amager Hospital; University Hospital Bispebjerg and Frederiksberg; Bornholm Hospital; Gentofte Hospital; Glostrup University Hospital, Copenhagen; Herlev Hospital; Hvidovre University Hospital; Nordsjaellands Hospital; Holbaek Hospital; Nykoebing Hospital; Naestved Hospital; Zealand University Hospital; Slagelse Hospital; Odense University Hospital; Svendborg Hospital; Sydvestjysk Sygehus; Hospital of Southern Jutland; Sygehus Lillebaelt (Vejle and Kolding); Aarhus University Hospital; Hospitalsenheden Midt; Hospitalsenheden Vest; Regionshospitalet Horsens; Silkeborg Sygehus; Aalborg University Hospital
- First posted
- Dec 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine whether long-term treatment with oral betablocker therapy after myocardial infarction in patient with no heart failure reduces the composite outcome of recurrent MI, all-cause mortality, revascularisation with percutaneous coronary intervention or coronary artery bypass graft, ischemic stroke, incident heart failure, or malignant ventricular arrhythmia including resuscitated cardiac arrest of cardiac origin.
Conditions
- Acute Myocardial Infarction
- Non-ST Elevation Myocardial Infarction (nSTEMI)
- ST Elevation Myocardial Infarction
Interventions
Metoprolol SuccinateDrug
Eligible patients randomized to receive long-term therapy with oral beta-blockade
BisoprololDrug
Eligible patients randomized to receive long-term therapy with oral beta-blockade
CarvedilolDrug
Eligible patients randomized to receive long-term therapy with oral beta-blockade
NebivololDrug
Eligible patients randomized to receive long-term therapy with oral beta-blockade
Primary outcomes
What the sponsor says the trial is designed to measure.
- A composite of all-cause mortality, recurrent MI, revascularisation with PCI or CABG, ischemic stroke, incident heart failure, or malignant ventricular arrhythmia including resuscitated cardiac arrest of cardiac origin.Time frame: Estimated follow-up min 6 months - max 6.25 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bispebjerg Hospital, Dept. of Cardiology Y builing 67, 1.floor, Bispebjerg Bakke 23
Copenhagen, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.